Meta-analysis of the Prognostic Value of Circulating Tumor Cells Detected with the CellSearch System in Colorectal Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Apr 17

PMID 25880692

Citations 71

Authors

Xuanzhang Huang

Peng Gao

Yongxi Song

Jingxu Sun

Xiaowan Chen

Junhua Zhao

Huimian Xu

Zhenning Wang

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of circulating tumor cells (CTCs) detected with the CellSearch System in patients with colorectal cancer (CRC) is controversial. The aim of our meta-analysis was to evaluate whether the detection of CTCs in the peripheral blood with the standardized CellSearch System has prognostic utility for patients with CRC.

Methods: The PubMed, Science Citation Index, Cochrane Database, Embase, and the references in relevant studies were systematically searched (up to December, 2014). No search restrictions were imposed. Our meta-analysis was performed in Stata software, version 12.0 (2011) (Stata Corp, College Station, TX, USA), with the odds ratio (OR), risk ratio (RR), hazard ratio (HR), and 95% confidence interval (95% CI) as the effect measures. Subgroup and sensitivity analyses were also conducted.

Results: Eleven studies containing 1847 patients with CRC were analyzed. There was a significantly higher incidence of CTCs in the metastasis-positive group than in the metastasis-negative group (OR = 4.06, 95% CI [1.74, 9.50], P < 0.01, I(2) = 0%). For hepatic metastasis, a type of metastasis, a higher incidence of CTCs was observed in the hepatic-metastasis-positive group than in the -negative group (OR = 2.61, 95% CI [1.73, 3.96], P < 0.01, I(2) = 0%). The presence of CTCs was significantly related to overall survival (HR = 2.00, 95% CI [1.49, 2.69], P < 0.01, I(2) = 67.1%) and progression-free survival (HR = 1.80, 95% CI [1.52, 2.13], P < 0.01, I(2) = 43.9%) of patients with CRC, regardless of the sampling time. The response rate for the CTC(+) groups was significantly lower than that for the CTC(-) groups at baseline and during treatment (baseline: 33% versus 39%, RR = 0.79, 95% CI [0.63, 0.99], P = 0.04, I(2) = 7.0%; during treatment: 17% versus 46%, RR = 0.41, 95% CI [0.22, 0.77], P = 0.01, I(2) = 0.0%;).

Conclusions: Our meta-analysis indicates that the detection of CTCs in the peripheral blood with the CellSearch System has prognostic utility for patients with CRC.

Citing Articles

Phenotypic diversity of CTCs and tdEVs in liquid biopsies of tumour-draining veins is linked to poor prognosis in colorectal cancer.

Cieslik S, Zafra A, Driemel C, Sudarsanam M, Cieslik J, Flugen G J Exp Clin Cancer Res. 2025; 44(1):9.

PMID: 39773651 PMC: 11708080. DOI: 10.1186/s13046-024-03259-6.

Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?.

Fabisiewicz A, Szostakowska-Rodzos M, Grzybowska E Int J Mol Sci. 2024; 25(19).

PMID: 39408942 PMC: 11476589. DOI: 10.3390/ijms251910612.

Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.

Chen T, Wang M, Chen Y, Cao Y, Liu Y Cell Biosci. 2024; 14(1):117.

PMID: 39267195 PMC: 11391723. DOI: 10.1186/s13578-024-01283-9.

Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?.

Radhakrishnan V, Kaifi J, Suvilesh K Cancers (Basel). 2024; 16(4).

PMID: 38398206 PMC: 10887304. DOI: 10.3390/cancers16040816.

Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?.

Magri V, Marino L, De Renzi G, De Meo M, Salvatori F, Buccilli D Biomedicines. 2024; 12(2).

PMID: 38397990 PMC: 10887063. DOI: 10.3390/biomedicines12020388.

References

Lucci A, Hall C, Lodhi A, Bhattacharyya A, Anderson A, Xiao L . Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012; 13(7):688-95. DOI: 10.1016/S1470-2045(12)70209-7. View

Seymour M, Maughan T, Ledermann J, Topham C, James R, Gwyther S . Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370(9582):143-152. DOI: 10.1016/S0140-6736(07)61087-3. View

Chen W, Chung M, Liu J, Liu J, Lin J . Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery. World J Surg. 2004; 28(6):552-7. DOI: 10.1007/s00268-004-7276-9. View

Wong S, Ng S, Cheung M, Luk L, Chan C, Cheung A . Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. Br J Cancer. 2011; 104(6):1000-6. PMC: 3065272. DOI: 10.1038/bjc.2011.32. View

Molnar B, Sipos F, Galamb O, Tulassay Z . Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis. 2004; 21(4):320-5. DOI: 10.1159/000075355. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Sadahiro S, Suzuki T, Maeda Y, Yurimoto S, Yasuda S, Makuuchi H . Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol. 2007; 14(3):1092-8. DOI: 10.1245/s10434-006-9289-0. View

Lim S, Becker T, Chua W, Caixeiro N, Ng W, Kienzle N . Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Lett. 2013; 346(1):24-33. DOI: 10.1016/j.canlet.2013.12.019. View

Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H . Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004; 566(1):9-20. DOI: 10.1016/s1383-5742(03)00033-4. View

10.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

11.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

12.

Torino F, Bonmassar E, Bonmassar L, De Vecchis L, Barnabei A, Zuppi C . Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev. 2013; 39(7):759-72. DOI: 10.1016/j.ctrv.2012.12.007. View

13.

Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O . Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?. J Cancer Res Clin Oncol. 2013; 139(8):1411-6. DOI: 10.1007/s00432-013-1450-0. View

14.

Sastre J, Vidaurreta M, Gomez A, Rivera F, Massuti B, Reboredo Lopez M . Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2013; 12(4):280-6. DOI: 10.1016/j.clcc.2013.06.001. View

15.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

16.

Heiss M, Strohlein M, Jager M, Kimmig R, Burges A, Schoberth A . Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005; 117(3):435-43. DOI: 10.1002/ijc.21165. View

17.

Aznavoorian S, Murphy A, Stetler-Stevenson W, Liotta L . Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993; 71(4):1368-83. DOI: 10.1002/1097-0142(19930215)71:4<1368::aid-cncr2820710432>3.0.co;2-l. View

18.

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

19.

Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E . Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013; 33(9):3905-10. View

20.

Groot Koerkamp B, Rahbari N, Buchler M, Koch M, Weitz J . Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013; 20(7):2156-65. DOI: 10.1245/s10434-013-2907-8. View